UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q/A

Amendment No. 1 

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2014

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ______ to ______.

Commission File Number: 000-54346

MEDYTOX SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Nevada	90-0902-741
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)
400 South Australian Ave., 8th Floor West Palm Beach, FL	33401
(Address of principal executive offices)	(Zip Code)

(561) 855-1626

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer o	Accelerated filer o
Non-accelerated filer o (Do not check if a smaller reporting company)	Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of November 17, 2014, the registrant had 29,306,026 shares of its Common Stock, $0.0001 par value, outstanding.

EXPLANATORY NOTE

This Amendment No. 1 to the Quarterly Report on Form 10-Q/A (the “Amendment”) amends the Quarterly Report on Form 10-Q of Medytox Solutions, Inc. (the “Company”) for the quarter ended September 30, 2014 (the “Original Filing”) that was originally filed with the Securities and Exchange Commission on November 19, 2014 to remove the statement in Notes 1 and 7 that the independent accountants had not completed their review. The independent accountants have completed their review and their report is included herein. The acknowledgement letter of the independent registered public accounting firm is included herein as Exhibit 15. This Amendment includes other changes to the previously filed Form 10-Q as follows: i) eliminate the disclosures in Notes 1 and 7 to the Condensed Consolidated Financial Statements relating to the evaluation of the historical accounting treatment of the Company’s Series B Preferred Shares; ii) include disclosures in Note 1 to the Condensed Consolidated Financial Statements pertaining to the correction of the provision for bad debts; iii) modify disclosures in Note 11 to include discussion of a subsequent event; and iv) modify discussions in Item 4 (Controls and Procedures) to report a material weakness in the Company’s internal controls over financial reporting, and actions to remediate the material weakness. As required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, the Company’s principal executive officer and principal financial officer are providing currently dated certifications, set forth as Exhibits 31.1, 31.2, 32.1 and 32.2 to this Amendment. Thus, the Company hereby amends Item 6 of the Original Filing to add such currently dated certifications, the acknowledegement letter and updated XBRL files as Exhibits.

Except as described above, the Amendment does not modify or update the disclosures presented in, or exhibits to, the Original Filing in any way.

MEDYTOX SOLUTIONS, INC.

FORM 10-Q

SEPTEMBER 30, 2014

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION		3
Item 1.	Financial Statements	3
	Condensed Consolidated Balance Sheets as of September 30, 2014 (unaudited) and December 31, 2013	3
	Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2014 and 2013 (unaudited)	5
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2014 and 2013 (unaudited)	6
	Notes to Condensed Consolidated Financial Statements (unaudited)	8
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	26
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	31
Item 4.	Controls and Procedures	31
PART II – OTHER INFORMATION		32
Item 1.	Legal Proceedings	32
Item 1A.	Risk Factors	32
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	32
Item 3.	Defaults Upon Senior Securities	32
Item 4.	Mine Safety Disclosures	32
Item 5.	Other Information	32
Item 6.	Exhibits	33
SIGNATURES		34

2

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

MEDYTOX SOLUTIONS, INC.

Condensed Consolidated Balance Sheets

	September 30,		December 31,
	2014		2013
	(unaudited)
ASSETS
Current assets:
Cash	$	1,763,728	$	4,141,416
Accounts receivable, net		21,375,024		10,986,368
Prepaid expenses and other current assets		334,108		194,137
Deferred tax assets		686,700		1,748,600
Assets attributable to disputed activity		–		1,367,796
Total current assets		24,159,560		18,438,317
Property and equipment, net		5,328,297		2,156,381
Other assets:
Intangible assets		3,190,613		3,190,613
Goodwill		5,317,347		1,425,999
Deposits		173,278		96,747
Total assets	$	38,169,095	$	25,308,057

See accompanying notes to condensed consolidated financial statements.

3

MEDYTOX SOLUTIONS, INC.

Condensed Consolidated Balance Sheets (Continued)

	September 30,		December 31,
	2014		2013
	(unaudited)
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable	$	2,301,101	$	1,755,965
Accrued expenses		3,365,644		2,855,884
Income tax liabilities		9,557,545		6,052,740
Disputed net income - Trident		–		397,918
Current portion of notes payable		800,000		3,689,554
Current portion of capital lease obligations		727,601		193,095
Liabilities attributable to disputed activity		–		1,104,063
Total current liabilities		16,751,891		16,049,219
Other liabilities:
Notes payable, net of current portion		100,000		42,107
Capital lease obligations, net of current portion		1,617,727		405,718
Deferred tax liabilities		42,000		41,800
Total liabilities		18,511,618		16,538,844
Commitments and contingencies
Stockholders' equity:
Preferred stock, 100,000,000 shares authorized:
Series B preferred stock, $0.0001 par value, 5,000 shares authorized, 5,000 and 5,000 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively		1		1
Series C preferred stock, $0.0001 par value, 1,000,000 shares authorized, nil shares issued and outstanding at each of September 30, 2014 and December 31, 2013		–		–
Series D preferred stock, $0.0001 par value, 200,000 shares authorized, 200,000 and nil shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively		20		–
Series E preferred stock, $0.0001 par value, 100,000 shares authorized, 100,000 and nil shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively		10		–
Common stock, $0.0001 par value, 500,000,000 shares authorized, 29,039,386 and 29,996,386 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively		2,904		3,000
Additional paid-in-capital		5,062,539		1,905,223
Deferred issuance costs		–		(12,500	)
Retained earnings		14,470,999		6,752,485
Total Medytox Solutions stockholders' equity		19,536,473		8,648,209
Noncontrolling interest		121,004		121,004
Total stockholders' equity		19,657,477		8,769,213
Total liabilities and stockholders' equity	$	38,169,095	$	25,308,057

See accompanying notes to condensed consolidated financial statements.

4

MEDYTOX SOLUTIONS, INC.

Condensed Consolidated Statements of Operations

(unaudited)

	For the Three Months Ended						For the Nine Months Ended
	September 30,						September 30,
	2014			2013			2014			2013
Revenues
Gross charges (net of contractual allowances and discounts)	$	22,829,064		$	16,729,526		$	64,676,062		$	33,355,862
Provision for bad debts		(4,613,097	)		(3,717,376	)		(15,630,857	)		(7,794,361	)
Net Revenues	$	18,215,967		$	13,012,150		$	49,045,205		$	25,561,501
Operating expenses:
Direct costs of revenue		4,136,520			3,291,530			11,601,402			6,987,777
General and administrative		5,898,715			4,529,506			14,075,030			9,171,359
Legal fees related to disputed subsidiary		–			267,286			94,217			857,587
Sales and marketing expenses		1,472,298			691,159			3,507,582			1,923,843
Depreciation and amortization		404,557			118,998			800,727			323,031
Total operating expenses		11,912,090			8,898,479			30,078,958			19,263,597
Income from operations		6,303,877			4,113,671			18,966,247			6,297,904
Other income (expense):
Other income		152			64			405			273
Gain on settlement of assets		–			400			–			750
Gain on disposition of subsidiary					–			134,185			–
Loss on legal settlement		–			(100,000	)		–			(169,800	)
Interest expense		(118,603	)		(68,785	)		(316,299	)		(332,387	)
Total other income (expense)		(118,451	)		(168,321	)		(181,709	)		(501,164	)
Income before income taxes		6,185,426			3,945,350			18,784,538			5,796,740
Provision for income taxes		2,454,205			1,141,000			7,250,305			1,655,900
Net income attributable to Medytox Solutions		3,731,221			2,804,350			11,534,233			4,140,840
Preferred stock dividends		1,391,614			913,132			3,815,719			1,396,238
Net income attributable to Medytox Solutions common shareholders	$	2,339,607		$	1,891,218		$	7,718,514		$	2,744,602
Net income per common share:
Basic	$	0.08		$	0.06		$	0.26		$	0.09
Diluted	$	0.08		$	0.06		$	0.25		$	0.09
Weighted average number of common shares outstanding during the period:
Basic		30,281,386			29,692,110			30,186,893			29,610,287
Diluted		30,741,651			30,217,565			30,565,526			30,059,226

See accompanying notes to condensed consolidated financial statements.

5

MEDYTOX SOLUTIONS, INC.

Condensed Consolidated Statements of Cash Flows

(unaudited)

	Nine Months Ended
	September 30,
	2014			2013
Cash flows from (used in) operating activities:
Net income	$	11,534,233		$	4,140,840
Adjustments to reconcile net income to net cash provided by operations:
Depreciation and amortization		800,727			323,031
Stock issued in lieu of cash compensation		162,500			–
Stock issued for services		–			62,500
Stock-based compensation		394,750			452,500
Stock-based consulting fees		–			85,000
Bad debts		15,630,857			7,794,361
Accretion of loan costs as interest		–			155,342
Accretion of beneficial conversion feature as interest		3,278			34,532
Write-off of deferred issuance costs		12,500			–
Gain on disposition of subsidiary		(134,185	)		–
Gain on disposal of equipment		–			(750	)
Changes in operating assets and liabilities:
Accounts receivable		(25,792,226	)		(11,647,148	)
Prepaid expenses and other current assets		(139,730	)		(25,078	)
Deferred tax assets		1,061,900			787,500
Security deposits		(75,831	)		(131,213	)
Accounts payable		185,108			704,636
Accrued expenses		791,541			1,497,823
Income tax liabilities		3,504,805			789,200
Deferred tax liabilities		200			79,200
Net cash provided by operating activities		7,940,427			5,102,276
Cash flows provided by (used in) investing activities:
Purchase of property and equipment		(1,417,979	)		(862,645	)
Cash received in sale of property and equipment		–			750
Cash paid for acquisitions		(1,600,000	)		(735,052	)
Cash received in acquisitions		31,671			3,735
Net cash used in investing activities		(2,986,308	)		(1,593,212	)
Cash flows provided by (used in) financing activities:
Proceeds from the sale of common stock		–			116,000
Deferred issuance costs		–			(103,949	)
Dividends on Series B preferred stock		(3,815,719	)		(1,396,238	)
Proceeds from issuance of notes payable		–			1,300,000
Payments on notes payable		(3,234,939	)		(2,278,910	)
Payments on capital lease obligations		(281,149	)		(86,705	)
Payments on related party loans		–			(195,000	)
Common stock repurchased from lender		–			(100,000	)
Net cash used in financing activities		(7,331,807	)		(2,744,802	)
Net increase (decrease) in cash		(2,377,688	)		764,262
Cash at beginning of period		4,141,416			1,773,785
Cash at end of period	$	1,763,728		$	2,538,047

See accompanying notes to condensed consolidated financial statements.

Continued

6

MEDYTOX SOLUTIONS, INC.

Condensed Consolidated Statements of Cash Flows (Continued)

(unaudited)

	Nine Months Ended September 30,
	2014			2013
Supplemental disclosure of cash flow information:
Cash paid for interest	$	258,087		$	257,963
Cash paid for taxes	$	2,720,498		$	–
Non-cash investing and financing activities:
Net liabilities acquired in acquisitions, net of cash	$	1,212,331		$	1,565,613
Goodwill	$	(3,891,348	)	$	(2,640,613	)
Contingent acquisition liability	$	54,017		$	–
Acquisition payment liabilities	$	150,000		$	–
Notes payable issued	$	400,000		$	1,075,000
Common stock	$	1		$	–
Series D preferred stock	$	20		$	–
Series E preferred stock	$	10		$	–
Additional paid in capital	$	2,074,969		$	–
Property and equipment acquired with issuance of notes payable	$	–		$	(56,603	)
Notes payable issued	$	–		$	56,603
Common stock issued as payment of accrued bonuses:
Accrued bonuses	$	(525,000	)	$	–
Common stock	$	21		$	–
Additional paid in capital	$	524,979		$	–
Capital lease assets acquired	$	(2,027,664	)	$	–
Capital lease obligations	$	2,027,664		$	–
1,241,550 common shares returned and cancelled from Officer and Director:
Common stock	$	(124	)	$	–
Additional paid in capital	$	124		$	–
Related party loans forgiven:
Loans and notes payable, related parties	$	–		$	(47,100	)
Additional paid in capital	$	–		$	47,100
Beneficial conversion feature of convertible notes payable:
Notes payable	$	–		$	(55,558	)
Additional paid in capital	$	–		$	55,558
Adjustment to purchase price for Biohealth Medical Laboratory, Inc.:
Goodwill	$	–		$	29,024
Notes payable issued	$	–		$	(24,678	)
Accrued expenses	$	–		$	(4,346	)
Adjustment to purchase price for Medical Billing Choices, Inc.:
Goodwill	$	–		$	(400,000	)
Common Stock	$	–		$	16
Additional paid in capital	$	–		$	399,984

See accompanying notes to condensed consolidated financial statements.

7

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 1 – Organization and Presentation

Organization

Medytox Solutions, Inc. (the “Company”) was incorporated in Nevada on July 20, 2005 as Casino Players, Inc. In the first half of 2011, Company management decided to reorganize the operations of the Company as a holding company to acquire and manage a number of companies in the medical services sector.

On March 18, 2014, the Company's wholly-owned subsidiary, Medytox Information Technology, Inc. (“MIT”), purchased 100% of the stock of Clinlab, Inc. ("Clinlab"). Clinlab develops and markets laboratory information management systems.

On May 9, 2014, the Company formed Medical Mime, Inc. (“Mime”), a Florida corporation, as a wholly-owned subsidiary.

On May 23, 2014, Mime purchased certain net assets, primarily consisting of software, of GlobalOne Information Technologies, LLC (“GlobalOne”). GlobalOne developed software and provided services for the Electronic Health Records (“EHR”) segment of the medical industry.

On August 26, 2014, the Company's wholly-owned subsidiary, Medytox Diagnostics, Inc. (“MDI”), purchased 100% of the stock of Epinex Diagnostics Laboratories, Inc. ("Epinex"), a clinical laboratory in Tustin, California.

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited interim condensed consolidated financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows for the interim periods reported in this Form 10-Q. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

These unaudited interim condensed consolidated financial statements should be read in conjunction with the 2013 audited annual financial statements included in the Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission (“SEC”) on March 31, 2014.

Revenue Recognition

Service revenues are principally generated from laboratory testing services including chemical diagnostic tests such as blood analysis and urine analysis. Net service revenues are recognized at the time the testing services are performed and are reported at their estimated net realizable amounts.

Net service revenues are determined utilizing gross service revenues net of contractual allowances. Even though it is the responsibility of the patient to pay for laboratory service bills, most individuals in the United States have an agreement with a third party payor such as Medicare, Medicaid or a commercial insurance provider to pay all or a portion of their healthcare expenses; the majority of services provided by Medytox are to patients covered under a third party payor contract. In certain cases, the individual has no insurance or does not provide insurance information. Despite follow up billing efforts, the Company does not currently anticipate collection of a significant portion of self-pay billings including the patient responsibility portion of the billing for patients covered by third party payors. The Company currently does not have any capitated agreements. In the remainder of the cases, Medytox is provided the third party billing information and seeks payment from the third party under the terms and conditions of the third party payor for health service providers like Medytox. Each of these third party payors may differ not only with regard to rates, but also with regard to terms and conditions of payment and providing coverage (reimbursement) for specific tests. Estimated revenues are established based on a series of procedures and judgments that require industry specific healthcare experience and an understanding of payor methods and trends.

We review our calculations on a monthly basis in order to make certain that we are properly allowing for the uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payor groups. The contractual allowance calculation is made on the basis of historical allowance rates for the various specific payor groups on a monthly basis with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions and shifts in the testing being performed. The provision for bad debts represents our estimate of net revenues that will ultimately be uncollectable and is based upon our analysis of historical payment rates by specific payor groups on a monthly basis with primary weight being given to the most recent trends; this approach allows bad debt to more accurately adjust to short-term changes in the business environment. These two calculations are routinely analyzed by Medytox on the basis of actual allowances issued by payors and the actual payments made to determine what adjustments, if any, are needed.

Contractual Allowances and Doubtful Accounts

Accounts receivable are reported at realizable value, net of allowances for contractual credits and doubtful accounts, which are estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimate and review the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to allowances for contractual credits and doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues which may impact the collectability of these receivables or reserve estimates. Receivables deemed to be uncollectible are charged against the allowance for doubtful accounts at the time such receivables are written-off. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts. Historically, revisions to the allowances for doubtful accounts estimates were recorded as an adjustment to the provision for bad debt within selling, general and administrative expenses.

During the third quarter of 2014, the Company corrected the classification of the provision for bad debts from a component of operating expenses to a reduction in revenues in our Condensed Consolidated Statements of Operations. This presentation is required under U.S. GAAP due to the uncertainties of collection of the self-pay portion of patent service revenues.

The effect of this correction reduced both net revenues and total operating expenses by approximately $3.7 million and $7.8 million for the three and nine months ended September 30, 2013, respectively. The correction has no effect on any previously reported balance sheet line item, income from operations or net income. Management has concluded that the effect of this change was not material to the financial statements taken as a whole. As such management followed the guidance of Staff Accounting Bulletin topic 1:N “Considering the Effects of the Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements” and made this immaterial correction by revising all prior periods in current and future filings.

Accounts receivable are presented net of allowances for uncollectible amounts of $12,262,894 and $3,621,814 at September 30, 2014 and December 31, 2013, respectively.

Reclassifications

Certain other items on the statements of operations for the three and nine months ended September 30, 2013 and the statement of cash flows for the nine months ended September 30, 2013 have been reclassified to conform to current period presentation.

8

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 2 – Disputed Subsidiary

On July 2, 2013, a jury awarded our wholly-owned subsidiary, Medytox Institute of Laboratory Medicine, Inc. ("MILM"), $2,906,844 on its breach of contract claim against Trident Laboratories, Inc. ("Trident"), and Trident's shareholders, Michele Steegstra, Christopher Hawley, Donette Hawley, Michael Falestta and Skyler Lukas ("Shareholders"), and awarded Seamus Lagan $750,000 individually against Christopher Hawley for Mr. Hawley's defamatory postings on the internet. The jury rejected every claim made against the MILM parties. All appeals have been dismissed.

The case arose from the August 22, 2011 agreement among MILM and Trident and its Shareholders pursuant to which MILM was to acquire 81% of Trident. On January 17, 2012, Trident notified MILM that it was rescinding the agreement. As a result, MILM filed suit against Trident and its Shareholders in Florida Circuit Court in Broward County. The jury found that Trident and its Shareholders breached the agreement and failed to perform their obligations thereunder.  

Legal fees related to the lawsuit were $-0- and $267,286 for the three months ended September 30, 2014 and 2013, respectively, and $94,217 and $857,587 for the nine months ended September 30, 2014 and 2013, respectively.

The Company has not received any financial statements of Trident since August 31, 2012. The consolidated financial statements of the Company were prepared without the financial information relating to Trident.  Management believes that the financial information relating to Trident is immaterial to the consolidated financial statements as a whole. The Company had established a disputed net income reserve of $397,918 as of December 31, 2013, representing all of Trident's net income recognized by the Company since August 22, 2011, the date of acquisition. The assets and liabilities of Trident had been condensed and presented as assets, or liabilities, attributable to disputed activity in the December 31, 2013 consolidated balance sheet. A separate $389,135 of commissions payable on Trident sales was included in liabilities attributable to disputed activity as of December 31, 2013. Effective March 31, 2014, the Company’s management believed that the net assets of Trident are not recoverable and, as such, the Company has accounted for the disputed assets and liabilities as if they have been disposed, resulting in a gain on the disposition of $134,185.

Assets and liabilities of the disputed subsidiary as of September 30, 2014 and December 31, 2013 were as follows:

	September 30,		December 31,
	2014		2013
Total assets	$	-0-	$	1,367,796
Total liabilities	$	-0-	$	1,104,063

Note 3 – Long-Lived Assets

Property and equipment at September 30, 2014 and December 31, 2013 consisted of the following:

	September 30,			December 31,
	2014			2013
Medical equipment	$	824,328		$	655,125
Equipment		256,918			111,265
Equipment under capital leases (See Note 6 - Capital Lease Obligations)		3,008,613			980,948
Furniture		234,199			206,587
Leasehold improvements		886,860			243,983
Vehicles		292,509			177,534
Computer equipment		475,161			235,507
Software		890,179			285,175
		6,868,767			2,896,124
Less accumulated depreciation		(1,540,470	)		(739,743	)
Property and equipment, net	$	5,328,297		$	2,156,381

9

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 3 – Long-Lived Assets (Continued)

Depreciation of property and equipment was $800,727 and $323,031 for the nine months ended September 30, 2014 and 2013, respectively.

Management has retained a third party valuation firm to assist in the valuation the identifiable intangible assets acquired and the equity portion of the consideration given to the seller. Until the valuation is complete and final values are assigned to the identifiable intangible assets acquired, the entire amount of the excess of the estimated consideration given over the working capital acquired, has been provisionally allocated to goodwill. See Note 9 – Business Combinations.

Management periodically reviews the valuation of long-lived assets for potential impairments. Management has not recognized an impairment of these assets to date, and does not anticipate any negative impact from known current business developments. The Company anticipates completing the annual impairment analysis in early December.

Note 4 – Notes Payable

The Company and its subsidiaries are party to a number of loans with affiliates and unrelated parties. At September 30, 2014 and December 31, 2013, notes payable consisted of the following:

	September 30,		December 31,
	2014		2013
Convertible debenture for working capital, dated September 15, 2011, in the amount of $500,000 and bearing interest at 20%. The note was convertible at $2.50 per share. The due date of the note was extended from October 31, 2013 to February 5, 2014 by the lender. The note was paid in full on February 5, 2014.	$	–	$	100,000
Loan from TCA. Principal of $2,475,000 and $2,475,000, respectively, payable by January 15, 2014. The note was extended from January 15, 2014 to September 15, 2014 and was secured by all assets of the Company and its subsidiaries (other than Trident and MBC). See "TCA Global" below.		–		2,475,000
Acquisition note No.1 to former shareholder of Alethea Laboratories, Inc. in the amount of $287,500 at 0% interest, with payments of $50,000 due quarterly starting April 1, 2013.		–		150,000
Acquisition note No. 2 to former shareholder of Alethea Laboratories, Inc. in the amount of $287,500 at 0% interest, with payments of $50,000 due quarterly starting April 1, 2013.		–		150,000
Loan from former shareholders of Alethea Laboratories, Inc. in the amount of $344,650 at 4% interest, with principal payments of $24,618 due monthly starting March 15, 2013. The note was paid in full on April 1, 2014.		–		98,471
Commercial loan with a finance company, dated December 20, 2012, in the original amount of $18,249 and bearing interest at 12.59%. Principal and interest payments in the amount of $364 were payable for 72 months ending on January 3, 2019. This note was secured by a lien on a vehicle with a carrying value of $16,623 at December 31, 2013. The note was paid in full on March 26, 2014.		–		15,845
Commercial loan with a finance company, dated November 15, 2012, in the original amount of $18,008 and bearing interest at 15.07%. Principal and interest payments in the amount of $384 are payable for 72 months ending on November 30, 2018. This note was secured by a lien on a vehicle with a carrying value of $16,430 at December 31, 2013. The note was paid in full on March 26, 2014.		–		16,279

10

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 4 – Notes Payable (Continued)

	September 30,			December 31,
	2014			2013
Commercial loan with a finance company, dated November 28, 2012, in the original amount of $20,345 and bearing interest at 8.99%.  Principal and interest payments in the amount of $368 are payable for 72 months ending on January 12, 2019. This note was secured by a lien on a vehicle with a carrying value of $18,300 at December 31, 2013.  The note was paid in full on March 26, 2014.		–			17,676
Acquisition convertible note No. 1 to former member of International Technologies, LLC in the amount of $250,000 at 5% interest and was due January 17, 2014.  The note was convertible into the Company's common stock at a ten percent (10%) discount to the average market price for the thirty days prior to conversion.  The note is discounted for its unamortized beneficial conversion feature of $-0- and $1,639 at September 30, 2014 and December 31, 2013, respectively.  See "Acquisition Convertible Notes" below.		250,000			248,361
Acquisition convertible note No. 2 to former member of International Technologies, LLC in the amount of $250,000 at 5% interest and was due January 17, 2014.  The note was convertible into the Company's common stock at a ten percent (10%) discount to the average market price for the thirty days prior to conversion. The note is discounted for its unamortized beneficial conversion feature of $-0- and $1,639 at September 30, 2014 and December 31, 2013, respectively.   See "Acquisition Convertible Notes" below.		250,000			248,361
Loan from former member of International Technologies, LLC in the remaining amount of $416,667 at the date of acquisition, at 1% interest, with principal payments of $83,333 due quarterly starting June 7, 2013.  The note was paid in full on June 6, 2014.		–			166,668
Loan from former member of International Technologies, LLC in the remaining amount of $112,500 at the date of acquisition, at 1% interest, with principal payments of $22,500 due quarterly starting June 7, 2013.  The note was paid in full on June 6, 2014.		–			45,000
Loan payable to former shareholder of Epinex Diagnostic Laboratories, Inc. in the amount of $400,000, at 0% interest, with principal payments of $100,000 due in periodic installments from November 26, 2014 through February 26, 2016.		400,000			–
		900,000			3,731,661
Less current portion		(800,000	)		(3,689,554	)
Notes payable, net of current portion	$	100,000		$	42,107

11

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 4 – Notes Payable (Continued)

TCA Global

Under terms of the Senior Secured Revolving Credit Facility agreement with TCA Global Credit Master Fund, LP, originally signed May 12, 2012 and as subsequently amended, the Company executed an Amended and Restated Revolving Promissory Note, due January 15, 2014, in the amount of $3,025,000. The note was extended by the lender from January 15, 2014 to September 15, 2014. The borrowings under this facility were repaid in full on September 8, 2014.

Acquisition Convertible Notes

The Company has filed an action against Reginald Samuels and Ralph Perricelli seeking, among other things, a declaration that the convertible debentures in the aggregate amount of $500,000 that the Company issued to Mr. Samuels and Mr. Perricelli as part of the consideration for the purchase of their interests in International Technologies, LLC are null and void. Mr. Samuels and Mr. Perricelli have been served and the litigation is ongoing.

Note 5 – Related Party Transactions

On September 11, 2014, William Forhan resigned as Chief Executive Officer and Chairman and returned 1,241,550 restricted common shares to the Company, which were then retired. Mr. Forhan remains the owner of 1,241,551 restricted common shares.

Mr. Forhan was employed as the Company’s Chief Executive Officer pursuant to the terms of an employment agreement dated June 1, 2011, as amended as of September 1, 2013. In connection with his voluntary resignation he entered into an agreement, to be effective as of the date of appointment of a new Chief Executive Officer of the Company, pursuant to which he will receive a severance of $500,000, payable in two installments, the first of $200,000 was paid prior to the effective date of resignation, and the balance to be paid no later than August 31, 2016. In addition, the Agreement provided that Mr. Forhan could participate in any executive bonus plan adopted for calendar year 2014. Mr. Forhan also agreed under the Agreement that any Company stock options previously issued to him, would remain outstanding, subject to their terms, for no longer than 24 months such that the options will expire no later than August 31, 2016. In addition, the Agreement provided, among other things, for the return and cancellation of 1,241,550 shares of Common Stock owned by Mr. Forhan; for the release by Mr. Forhan of any and all claims he may have had against the Company and/or its affiliates; and for Mr. Forhan to abide by certain restrictive covenants, including using his best efforts to protect and maintain the Company's confidential information.

Note 6 – Capital Lease Obligations

The Company leases various assets under capital leases expiring through 2020 as follows:

	September 30,			December 31,
	2014			2013
Medical equipment	$	3,008,613		$	980,948
Less accumulated depreciation		(689,135	)		(364,726	)
Net	$	2,319,478		$	616,222

Depreciation expense on assets under capital leases was $324,409 and $98,340 for the nine months ended September 30, 2014 and 2013, respectively.

12

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 6 – Capital Lease Obligations (Continued)

Aggregate future minimum rentals under capital leases are as follows:

Future minimum rentals

December 31,
2014	$	227,810
2015		911,238
2016		771,302
2017		662,897
2018		75,667
Thereafter		68,186
Total		2,717,100
Less interest		371,772
Present value of minimum lease payments		2,345,328
Less current portion of capital lease obligations		727,601
Capital lease obligations, net of current portion	$	1,617,727

Note 7 – Stockholders’ Equity

Authorized Capital

The Company has 500,000,000 authorized shares of Common Stock at $0.0001 par value per share and 100,000,000 authorized shares of Preferred Stock at $0.0001 par value per share.

On October 1, 2012, the Company filed a certificate of designation with the Secretary of State of Nevada to designate 5,000 shares of Series B Non-convertible Preferred Stock, at $0.0001 par value per share.  The Series B shares do not include any voting rights and allow for monthly dividends in an amount equal to the sum of 1) 10% of the amount of gross sales in excess of $1 million collected in the ordinary course of business, not to exceed $150,000, and 2) 15% of the amount of gross sales in excess of $2.5 million collected in the ordinary course of business. At each of September 30, 2014 and December 31, 2013, there were 5,000 shares of Series B Preferred Stock outstanding.

On March 27, 2014, each of the holders of shares of Series B Preferred Stock entered into a purchase option agreement with the Company. Each agreement grants the Company an option to purchase any or all shares of Series B Preferred Stock held by the holder at any time through March 27, 2016 at a purchase price of $5,000 per share. Each holder agreed not to transfer or dispose of any shares of Series B Preferred Stock during the term of the option, other than to the Company upon an exercise of the option. Any exercise of an option is completely at the Company's discretion.

13

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 7 – Stockholders’ Equity (Continued)

Authorized Capital (Continued)

On October 7, 2012, the Company filed a certificate of designation with the Secretary of State of Nevada to designate 1,000,000 shares of Series C Convertible Preferred Stock, at $0.0001 par value per share. The Series C shares were convertible into shares of Common Stock by the quotient of 1 divided by the product of 0.80 multiplied by the market price of the Company’s Common Stock at the date of conversion. The Series C shares also included voting rights of 25 votes for every share of Series C Preferred Stock and were entitled to dividends at the same time any dividend was paid or declared on any shares of the Company’s Common Stock. Pursuant to their terms, all of the shares of Series C Preferred Stock were converted into shares of Common Stock on December 31, 2012.

On March 17, 2014, the Company filed a Certificate of Designation with the Secretary of State of Nevada authorizing up to 200,000 shares of Series D Convertible Preferred Stock at $0.0001 par value per share ("Series D Preferred Stock"). Each share of Series D Preferred Stock is convertible into the number of shares of Common Stock equal to the quotient of 5 divided by the product of 0.80 multiplied by the market price, as defined in Certificate of Designation, of the Company’s Common Stock at the date of conversion. After the earlier of the date the trading volume of the Common Stock exceeds an aggregate of 3,000,000 shares in any 30 day period or the date the Company sells shares of Common Stock in a firm commitment underwritten public offering with aggregate gross proceeds of at least $30,000,000, each share of Series D Preferred Stock shall be convertible into the number of shares of Common Stock equal to the quotient of (i) 5 divided by (ii) the market price of the Common Stock. All shares of Series D Preferred Stock outstanding on the second anniversary of the original issuance date shall be automatically converted into shares of Common Stock.

The Series D shares also include voting rights of 1 vote for every share of Series D Preferred Stock and are entitled to dividends, at the same time any dividend is paid or declared on any shares of the Company’s Common Stock The dividends are to be in an amount equal to the amount such holder would have received if the Series D Preferred Stock were converted to Common Stock. As of September 30, 2014 and December 31, 2013, there were 200,000 shares and no shares of Series D Preferred Stock outstanding, respectively.

On August 21, 2014, the Company filed a Certificate of Designation with the Secretary of State of Nevada authorizing 100,000 shares of Series E Convertible Preferred Stock at a par value of $.0001 per share. The Series E shares are convertible into the number of shares of Common Stock equal to the quotient of 8 divided by the average market price of the Company’s Common Stock for thirty trading days prior to the date of conversion, multiplied by the number of Series E shares being converted. Any Series E shares which remain outstanding on August 28, 2016 will be automatically converted into Common Stock using the prescribed formula. The Series E shares also include voting rights of 1 vote for every share of Series E Preferred Stock and are entitled to dividends at the same time any dividend is paid or declared on any shares of the Company’s Common Stock. The dividends are to be in an amount equal to the amount such holder would have received if the Series E Preferred Stock were converted to Common Stock at the same time any dividend is paid or declared on any shares of the Company’s Common Stock. As of September 30, 2014 and December 31, 2013, there were 100,000 shares and no shares of Series E Preferred Stock outstanding, respectively.

Preferred Stock

During the nine months ended September 30, 2014 and 2013, the Series B preferred shareholders earned dividends totaling $3,815,719 and $1,396,238, respectively.

14

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 7 – Stockholders’ Equity (Continued)

Preferred Stock (Continued)

On March 18, 2014, 200,000 shares of Series D Preferred Stock of the Company were issued to the previous owners of Clinlab pursuant to a stock purchase agreement whereby the Company purchased all of the outstanding stock of Clinlab (See Note 9 – Business Combinations).

On August 28, 2014, 100,000 shares of Series E Preferred Stock of the Company were issued to the previous owner of Epinex pursuant to a stock purchase agreement whereby the Company purchased all of the outstanding stock of Epinex (See Note 9 – Business Combinations).

Common Stock

During the nine months ended September 30, 2014, the Company issued an aggregate of 285,000 shares of the Company’s restricted common stock. The Company issued an aggregate of 210,000 shares under the Medytox Solutions, Inc. 2013 Incentive Compensation Plan to six management executives and one consultant as partial payment of bonuses which were accrued at December 31, 2013. The shares were valued at $2.50, based on the price of shares sold to investors, for a total of $525,000. An aggregate of 65,000 shares were issued to two employees pursuant to employment agreements, valued at $2.50, based on the price of shares sold to investors, for a total of $162,500. A total of 10,000 shares were issued to GlobalOne in connection with the acquisition of certain assets, valued at $2.50, based on the price of shares sold to investors, for a total of $25,000.

On September 11, 2014, William Forhan resigned as Chief Executive Officer and Chairman and returned 1,241,550 restricted common shares to the Company, which were then retired. Mr. Forhan remains the owner of 1,241,551 restricted common shares.

2013 Equity Plan

On September 25, 2013, the Company’s board of directors approved and adopted the Medytox Solutions, Inc. 2013 Incentive Compensation Plan (the “2013 Plan”). The 2013 Plan was approved by a majority of stockholders of the Company on November 22, 2013. The 2013 Plan provides for the grant of shares of common stock, options, performance shares, performance units, restricted stock, stock appreciation rights and other awards.

The following summarizes activity under the 2013 Plan for the nine months ended September 30, 2014:

Shares approved for issuance at plan inception	5,000,000
Options granted in 2014	(1,435,000	)
Options cancelled in 2014	10,000
Restricted shares issued in 2014	(210,000	)
Balance at September 30, 2014	3,365,000

15

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 7 – Stockholders’ Equity (Continued)

Stock Options

The following summarizes options outstanding at December 31, 2013 and option activity for the nine months ended September 30, 2014:

									Weighted
	Common Stock Options Outstanding								average
	Employees and			Non-					exercise
	Directors			employees		Total			price
Balance at December 31, 2013		20,150,000			3,020,000		23,170,000		$	5.33
Options granted		1,435,000			–		1,435,000			2.76
Options cancelled or expired		(210,000	)		–		(210,000	)		2.50
Balance at September 30, 2014		21,375,000			3,020,000		24,395,000		$	5.06

The following table summarizes information with respect to stock options outstanding and exercisable by employees and directors at September 30, 2014:

	Options outstanding							Options vested and exercisable
			Weighted
			average		Weighted					Weighted
			remaining		average	Aggregate				average	Aggregate
	Number		contractual		exercise	intrinsic		Number		exercise	intrinsic
Exercise price	outstanding		life (years)		price	value		vested		price	value
$2.50		8,625,000		3.76	$2.50	$	–		7,962,500	$2.50	$	–
$5.00		6,750,000		3.24	$5.00		–		6,600,000	$5.00		–
$10.00		6,000,000		8.26	$10.00		–		6,000,000	$10.00		–
		21,375,000			$5.39	$	–		20,562,500	$5.49	$	–

The following table summarizes information with respect to stock options outstanding and exercisable by non-employees at September 30, 2014:

	Options outstanding							Options vested and exercisable
			Weighted
			average		Weighted					Weighted
			remaining		average	Aggregate				average	Aggregate
	Number		contractual		exercise	intrinsic		Number		exercise	intrinsic
Exercise price	outstanding		life (years)		price	value		vested		price	value
$2.50		1,020,000		3.20	$2.50	$	–		1,020,000	$2.50	$	–
$5.00		1,000,000		3.25	$5.00		–		1,000,000	$5.00		–
$10.00		1,000,000		8.26	$10.00		–		1,000,000	$10.00		–
		3,020,000			$5.81	$	–		3,020,000	$5.81	$	–

16

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 7 – Stockholders’ Equity (Continued)

Stock Options (Continued)

During the nine months ended September 30, 2014, the Company issued options to purchase a total of 100,000 shares of the Company’s common stock to an employee pursuant to terms of an employment agreement. These options have contractual lives of two years and were valued at an average grant date fair value of $0.25 per option, or $25,000, using the Black-Scholes Option Pricing Model with the following assumptions:

Stock price	$2.50
Expected term	1 year
Expected volatility	24.43%
Risk free interest rate	0.30%
Dividend yield	0

The stock price was based on the price of shares sold to investors and volatility was based on comparable volatility of other companies since the Company had no significant historical volatility. As the 100,000 options were vested as of September 30, 2014, $25,000 of stock-based compensation was recorded for the nine months ended September 30, 2014.

During the nine months ended September 30, 2014, the Company issued options to purchase a total of 1,035,000 shares of the Company’s common stock to various employees. These options have contractual lives of ten years and were valued at an average grant date fair value of $0.70 per option, or $724,500, using the Black-Scholes Option Pricing Model with the following assumptions:

Stock price	$2.50
Expected term	5.375 years
Expected volatility	27.72%
Risk free interest rate	1.46%
Dividend yield	0

The stock price was based on the price of shares sold to investors and volatility was based on comparable volatility of other companies since the Company had no significant historical volatility. As of September 30, 2014, 517,500 of these options had vested and the Company recognized $358,750 of stock-based compensation expense the nine and three months ended September 30, 2014.

During the nine months ended September 30, 2014, the Company issued options to purchase a total of 300,000 shares of the Company’s common stock to a director. These options have contractual lives of four years and were valued at an average grant date fair value of $0.18 per option, or $54,000, using the Black-Scholes Option Pricing Model with the following assumptions:

Stock price	$2.50
Expected term	2 years
Expected volatility	24.43%
Risk free interest rate	0.43%
Dividend yield	0

The stock price was based on the price of shares sold to investors and volatility was based on comparable volatility of other companies since the Company had no significant historical volatility. As of September 30, 2014, 200,000 of these options had vested and the Company recognized $36,000 of stock-based compensation expense the nine and three months ended September 30, 2014.

As of September 30, 2014, there were unrecognized compensation costs of $416,750 related to stock options. The Company expects to recognize those costs over a weighted average period of .35 years as of September 30, 2014. Future option grants will increase the amount of compensation expense to be recorded in these periods.

17

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 7 – Stockholders’ Equity (Continued)

Warrants

The following table summarizes warrant transactions for the nine months ended September 30, 2014:

					Weighted
			Weighted		average
			average		remaining		Aggregate
	Number		exercise		contractual		intrinsic
	of warrants		price		term (years)		value
Granted in 2013		346,400	$	3.22
Outstanding at December 31, 2013 and September 30, 2014		346,400	$	3.22		0.32	$	–
Exercisable at December 31, 2013 and September 30, 2014		346,400	$	3.22		0.32	$	–
Weighted Average Grant Date Fair Value			$	0.25

During the nine months ended September 30, 2013, the Company issued warrants to purchase a total of 46,400 shares of the Company’s common stock in conjunction with sales of Units. These warrants have contractual lives of twenty-four months and were valued at a grant date fair value of $-0- per warrant using the Black-Scholes Option Pricing Model with the following assumptions:

Stock price	$0.01
Contractual term	24 months
Expected volatility	29.13%
Risk free interest rate	0.15%
Dividend yield	0

During the nine months ended September 30, 2013, the Company issued warrants to purchase a total of 300,000 shares of the Company’s common stock to two individuals in connection with obligations entered into by the Company’s subsidiaries. These warrants have contractual lives of two years and were valued at an average grant date fair value of $0.283 per warrant, or $85,000, using the Black-Scholes Option Pricing Model with the following assumptions:

Stock price	$2.50
Contractual term	2 years
Expected volatility	29.13%
Risk free interest rate	0.27%
Dividend yield	0

The stock price was based on the price of shares sold to investors and volatility was based on comparable volatility of other companies since the Company had no significant historical volatility. The $85,000 was expensed as stock-based consulting fees for the nine months ended September 30, 2013.

18

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 7 – Stockholders’ Equity (Continued)

Basic and Diluted Income per Share

The Company computes income per share in accordance with ASC 260, "Earnings per Share", which requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the statement of operations. Basic EPS is computed by dividing income available to common shareholders by the weighted average number of shares outstanding during the period. Diluted EPS gives effect to all potential dilutive equivalent shares of common stock outstanding during the period using the treasury stock method and convertible debt and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options, convertible debt, convertible preferred stock, or warrants.

Basic and Diluted EPS were calculated as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2014		2013		2014		2013
Basic:
Numerator - net income available to common stockholders	$	2,339,607	$	1,891,218	$	7,718,514	$	2,744,602
Denominator - weighted-average shares outstanding		30,281,386		29,692,110		30,186,893		29,610,287
Net income per share - Basic	$	0.08	$	0.06	$	0.26	$	0.09
Diluted:
Numerator:
Net income available to common stockholders	$	2,339,607	$	1,891,218	$	7,718,514	$	2,744,602
Interest expense on convertible debt, net of taxes		3,750		13,285		11,250		39,856
	$	2,343,357	$	1,904,503	$	7,729,764	$	2,784,458
Denominator:
Weighted-average shares outstanding		30,281,386		29,692,110		30,186,893		29,610,287
Weighted-average equivalent shares from convertible debt		222,222		322,222		222,222		245,706
Weighted-average equivalent shares from Series C convertible preferred stock		–		203,233		–		203,233
Weighted-average equivalent shares from Series D convertible preferred stock		200,000		–		143,590		–
Weighted-average equivalent shares from Series E convertible preferred stock		38,043		–		12,821		–
		30,741,651		30,217,565		30,565,526		30,059,226
Net income per share - Diluted	$	0.08	$	0.06	$	0.25	$	0.09

Diluted EPS excludes all dilutive potential shares if their effect is anti-dilutive. As of September 30, 2014 and 2013, the following potential common stock equivalents were excluded from the calculation of Diluted EPS as their effect was anti-dilutive:

	September 30,
	2014		2013
Stock options outstanding		24,395,000		23,170,000
Warrants outstanding		346,400		346,400
		24,741,400		23,516,400

19

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 8 – Income Taxes

Significant components of the income tax provision are summarized as follows:

	September 30,
	2014		2013
Current provision:
Federal	$	5,300,405	$	2,042,400
State		887,800		218,100
Deferred provision:
Federal		959,500		(546,300	)
State		102,600		(58,300	)
	$	7,250,305	$	1,655,900

A reconciliation of the statutory federal income tax rate to the Company’s effective income tax rate on income before income taxes for the nine months ended September 30, 2014 and 2013 is as follows:

	September 30,
	2014		2013
Expected federal income tax at 34% statutory rate		35.0%		34.0%
State income taxes		3.5%		3.6%
Permanent differences		0.1%		0.0%
Change in valuation allowance		0.0%		0.0%
		38.6%		37.6%

The Company provides for income taxes using the liability method in accordance with FASB ASC Topic 740 “Income Taxes”. Deferred income taxes arise from the differences in the recognition of income and expenses for tax purposes. Deferred tax assets and liabilities are comprised of the following at September 30, 2014 and December 31, 2013:

	September 30,			December 31,
	2014			2013
Deferred income tax assets:
Allowance for bad debts	$	–		$	1,362,900
Accrued compensation		686,700			385,700
Stock options		318,800			170,300
Total deferred income tax assets	$	1,005,500		$	1,918,900
Deferred income tax liabilities:
Property and equipment	$	(105,000	)	$	(76,100	)
Intangible amortization		(255,800	)		(136,000	)
Total deferred income tax liabilities	$	(360,800	)	$	(212,100	)
Net deferred income taxes:
Current		686,700			1,748,600
Non-current		(42,000	)		(41,800	)
	$	644,700		$	1,706,800

20

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 8 – Income Taxes (Continued)

Management has reviewed the provisions regarding assessment of their valuation allowance on deferred tax assets and based on that criteria determined that it will have sufficient taxable income to realize those assets. Therefore, management has assessed the realization of the deferred tax assets and has determined that it is more likely than not that they will be realized.

The Company recognizes the consolidated financial statement impact of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than–not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

Note 9 – Business Combinations

The Company completed three acquisitions during the nine months ended September 30, 2014 and two during the year ended December 31, 2013. The Company accounted for the assets, liabilities and ownership interests in accordance with the provisions of FASB ASC 805 “Business Combinations”. As such, the recorded assets and liabilities acquired have been recorded at fair value and any difference in the net asset values and the consideration given has been recorded as a gain on acquisition or as goodwill.

Goodwill was attributable to the following subsidiaries as of September 30, 2014 and December 31, 2013:

	September 30,		December 31,
	2014		2013
Medical Billing Choices, Inc.	$	1,202,112	$	1,202,112
PB Laboratories, LLC		107,124		107,124
Biohealth Medical Laboratory, Inc.		116,763		116,763
Clinlab, Inc.		2,261,532		–
Medical Mime, Inc. (GlobalOne Information Technologies, LLC)		176,816		–
Epinex Diagnostic Laboratories Inc.		1,453,000		–
	$	5,317,347	$	1,425,999

The goodwill attributed to each of Clinlab, Inc. and Epinex Diagnostics Laboratories, Inc. and the assets acquired from GlobalOne Information Technologies, LLC, is subject to adjustment by management as described below.

Epinex Diagnostic Laboratories, Inc.

On August 26, 2014, the Company, through its subsidiary, MDI, purchased all of the outstanding stock of Epinex from an unrelated party. The purchase price was an aggregate of $1,300,000, $100,000 in cash, $400,000 loan payable, and 100,000 shares of Series E Preferred Stock of the Company, currently convertible into $800,000 of common stock of the Company at the date of conversion.

The following table summarizes the consideration given for Epinex and the fair values of the assets acquired and liabilities assumed recognized at the acquisition date. Management has retained a third party valuation firm to assist in the valuation the identifiable intangible assets acquired and the equity portion of the consideration given to the seller.  Until the valuation is complete and final values are assigned to the identifiable intangible assets acquired, the entire amount of the excess of the estimated consideration given over the working capital acquired, has been provisionally allocated to goodwill.

21

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 9 – Business Combinations (Continued)

Epinex Diagnostic Laboratories, Inc. (Continued)

Consideration Given:
Cash	$	100,000
Notes Payable		400,000
Series E Preferred Stock		800,000
Total consideration	$	1,300,000
Fair value of identifiable assets acquired and liabilities assumed:
Accounts receivable	$	80,000
Property and equipment		27,000
Accounts payable and accrued expenses		(260,000	)
Identified intangible assets		–
Total identifiable net assets		(153,000	)
Goodwill and unidentified intangible assets		1,453,000
	$	1,300,000

GlobalOne Information Technologies, LLC

On May 23, 2014, the Company, through its subsidiary, Mime, purchased certain net assets, primarily consisting of software, of GlobalOne. The purchase price was an aggregate of $675,000, $500,000 in cash, 10,000 shares of Common Stock, and $150,000 in cash payable six months after the date of closing.

The following table summarizes the consideration given for the net assets of GlobalOne and the fair values of the assets acquired and liabilities assumed recognized at the acquisition date. Management has retained a third party valuation firm to assist in the valuation the identifiable intangible assets acquired and the equity portion of the consideration given to the seller.  Until the valuation is complete and final values are assigned to the identifiable intangible assets acquired, the entire amount of the excess of the estimated consideration given over the working capital acquired, has been provisionally allocated to goodwill.

Consideration Given:
Cash	$	500,000
Common stock		25,000
Acquisition liability		150,000
Total consideration	$	675,000
Fair value of identifiable assets acquired and liabilities assumed:
Accounts receivable	$	93,270
Accounts payable and accrued expenses		(95,086	)
Software		500,000
Identified intangible assets		–
Total identifiable net assets		498,184
Goodwill and unidentified intangible assets		176,816
	$	675,000

22

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 9 – Business Combinations (Continued)

Clinlab, Inc.

On March 18, 2014, the Company, through its subsidiary, MIT, purchased all of the outstanding stock of Clinlab from two unrelated parties. The purchase price was an aggregate of $2,250,000, $1,000,000 in cash and 200,000 shares of Series D Preferred Stock of the Company, convertible into approximately $1,250,000 of common stock of the Company at the date of conversion.

The following table summarizes the consideration given for Clinlab and the fair values of the assets acquired and liabilities assumed recognized at the acquisition date. Management has retained a third party valuation firm to assist in the valuation the identifiable intangible assets acquired and the equity portion of the consideration given to the seller.  Until the valuation is complete and final values are assigned to the identifiable intangible assets acquired, the entire amount of the excess of the estimated consideration given over the working capital acquired, has been provisionally allocated to goodwill.

Consideration Given:
Cash	$	1,000,000
Series D Preferred Stock		1,250,000
Contingent acquisition liability		54,017
Total consideration	$	2,304,017
Fair value of identifiable assets acquired and liabilities assumed:
Cash	$	31,671
Accounts receivable		54,017
Prepaid expenses		241
Security deposit		700
Accounts payable and accrued expenses		(44,144	)
Identified intangible assets		–
Total identifiable net assets		42,485
Goodwill and unidentified intangible assets		2,261,532
	$	2,304,017

Note 10 – Commitments and Contingencies

Legal Matters

During the course of business, litigation commonly occurs.  From time to time the Company may be a party to litigation matters involving claims against the Company. The Company operates in a highly regulated industry and employs personnel which may inherently lend itself to legal matters.  Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company's financial position or results of operations. Management, in consultation with legal counsel, has addressed known assertions and unasserted claims below.

On July 2, 2013, a jury awarded Medytox Institute of Laboratory Medicine, Inc., our wholly-owned subsidiary ("MILM"), $2,906,844 on its breach of contract claim against Trident Laboratories, Inc. and its shareholders and awarded Seamus Lagan $750,000 individually against Christopher Hawley for defamatory postings on the internet. The jury rejected every claim made against the MILM parties. All appeals have been dismissed. Because of the uncertainties as to the collectability of amounts awarded, no amounts have been recorded by the Company.

The Company filed an action on February 14, 2014 in the United States District Court for the Southern District of Florida against Reginald Samuels and Ralph Perricelli seeking, among other things, a declaration that the convertible debentures in the aggregate amount of $500,000 that the Company issued to Mr. Samuels and Mr. Perricelli as part of the consideration for the purchase of their interests in International Technologies, LLC are null and void. Mr. Samuels and Mr. Perricelli have been served and the litigation is ongoing.

23

Medytox Solutions, Inc.

Notes to Consolidated Financial Statements

September 30, 2014

(unaudited)

Note 10 – Commitments and Contingencies (Continued)

Legal Matters (Continued)

On October 21, 2013, Mr. Samuels filed a complaint in the Superior Court of New Jersey (Bergen County) against the Company and Medytox Diagnostics, Inc. alleging breach of contract under his employment agreement and the agreement under which International Technologies, LLC was acquired; unjust enrichment; fraud; intentional and negligent misrepresentation; and breach of an implied duty of good faith and fair dealing and seeking an accounting. On December 20, 2013, Mr. Perricelli filed a similar action in the same court. The Company believes all these claims are without merit.

The action filed by Mr. Samuels has been removed to the federal court in the District of New Jersey. The action filed by Mr. Perricelli has been transferred to the Southern District of Florida.

Note 11 – Subsequent Events

On December 6, 2014, the Company and CollabRx, Inc. ("CollabRx") entered into a non-binding letter of intent for a potential business combination between the companies (the “Letter of Intent”). CollabRx develops and markets medical information and clinical decision support products and services intended to set a standard for the clinical interpretation of genomics-based, precision medicine in cancer. The business combination is subject to, among other things, due diligence, the execution of a definitive agreement, necessary board of director and stockholder approvals and other customary conditions.

Pursuant to the Letter of Intent, the Company has agreed to advance certain funding to CollabRx in contemplation of the business combination. On January 16, 2015, the Company entered into a Loan and Security Agreement with CollabRx, pursuant to which it is contemplated the Company will loan up to $2,395,644 to CollabRx and an Agreement with CollabRx, pursuant to which CollabRx agreed that in the event it enters into a merger or other sale transaction involving at least thirty-five percent (35.0%) of its shares or assets with a party other than the Company CollabRx will pay the Company a $1,000,000 fee.

On February 19, 2015, Medytox and CollabRx entered into an amendment to the Loan Agreement. The Amendment sets forth CollabRx’s agreement not to request any further advances from Medytox pursuant to the Loan Agreement until after it has spent at least the greater of (i) $1,500,000 of the proceeds of a recent offering by CollabRx of shares of its common stock and warrants or (ii) 60% of the net proceeds of the offering.

The Company has evaluated other subsequent events through the date the financial statements were issued and filed with the SEC. The Company has determined that there are no other subsequent events that warrant disclosure or recognition in the consolidated financial statements.

24

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

Board of Directors and Shareholders

Medytox Solutions, Inc.

We have reviewed the accompanying condensed consolidated balance sheet of Medytox Solutions, Inc., a Nevada corporation, and subsidiaries (the "Company'') as of September 30, 2014, and the related condensed consolidated statements of operations for the three-month and nine-month periods ended September 30, 2014 and cash flows for the nine-month period ended September 30, 2014. These interim financial statements are the responsibility of the Company's management.

We conducted our review in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the condensed consolidated interim financial statements referred to above for them to be in conformity with accounting principles generally accepted in the United States of America.

/S/ GRANT THORNTON LLP

Fort Lauderdale, FL

March 6, 2015

25

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

SPECIAL NOTE CONCERNING FORWARD-LOOKING STATEMENTS

Certain statements made in this Form 10-Q are "forward-looking statements" (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Company's plans and objectives are based, in part, on assumptions involving the continued expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove to be inaccurate and, therefore, there can be no assurance the forward-looking statements included in this report will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

The forward-looking statements included in this Form 10-Q and referred to elsewhere are related to future events or our strategies or future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "believe," "anticipate," "future," "potential," "estimate," "encourage," "opportunity," "growth," "leader," "expect," "intend," "plan," "expand," "focus," "through," "strategy," "provide," "offer," "allow," commitment," "implement," "result," "increase," "establish," "perform," "make," "continue," "can," "ongoing," "include" or the negative of such terms or comparable terminology. All forward-looking statements included in this Form 10-Q are based on information available to us as of the filing date of this report, and the Company assumes no obligation to update any such forward-looking statements, except as required by law. Our actual results could differ materially from the forward-looking statements.

Important factors that might cause our actual results to differ materially from the results contemplated by the forward-looking statements are contained in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2013 and in our subsequent filings with the Securities and Exchange Commission.  The following discussion of our results of operations should be read together with our financial statements and related notes included elsewhere in this report.

Company Overview

Medytox Solutions, Inc. (the “Company”, "Medytox", “we”, “us”, or “our”) is a holding company that owns and operates businesses in the medical services sector.  Our principal line of business is clinical laboratory blood and urine testing services, with a particular emphasis in the provision of urine drug toxicology and comprehensive pain medication monitoring programs to physicians, clinics and rehabilitation facilities in the United States.  For each of the nine-month periods ended September 30, 2014 and 2103, testing services to rehabilitation facilities represented over 90% of our revenues.

We offer a complete, turn-key urine drug testing (UDT) program allowing physicians to proactively monitor and treat patients. The Medytox UDT program is utilized by physicians to identify and evaluate prescribed and/or non-prescribed drugs that when combined may cause adverse drug interactions dangerous to a patient's health.  With our UDT program, physicians can be more assured their patients are adhering to their therapeutic drug regimens and are in compliance with their prescribed guidelines. Our UDT program helps the health care provider achieve better outcomes for patients and in evaluating to what extent the prescribed medications and their dosages are working for the patient to achieve a better outcome towards recovery.

In addition to our clinical testing operations, we provide a web-based portal to provide laboratory ordering and results to our physician customers. The Company also provides lab information systems and Electronic Health Records (“EHR”) and billing services to customers.

As a provider of clinical laboratory services, we continue to pursue our strategy of acquiring or entering into binding relationships with high-complexity laboratories that can facilitate our customers' needs. We have successfully completed several such acquisitions or strategic partnerships with laboratories located in different regions of the United States, allowing us to correspondingly increase our client base. These laboratories, and those we shall continue to seek out, offer or can be developed to offer the most advanced analytical technology for the processing of urine and blood specimens including Immunoassay Analyzers (IA) for screens and GCMS/LCMS for confirmations.  All Medytox laboratories, with the exception of the recently acquired Epinex, are fully-staffed professional COLA-accredited high-complexity laboratories with additional certifications such as the COLA Laboratory of Excellence Award (COLA's Highest Commendation), CLIA (Clinical Laboratory Improvement Amendments) and the State of Florida's AHCA Clinical Laboratory License for Non-Waived High Complexity testing. In the case of Epinex and any facilities acquired in the future we anticipate that the operations will meet these stringent requirements as they become fully operational in the Medytox group. Our in-house billing company services all of our acquired or allied facilities, utilizing electronic processing of claims to the major insurance payers and eliminating the need to rely on and pay for the services of clearing houses allowing us to maximize profit retention.

26

Company History

Medytox was organized on July 20, 2005 under the laws of the State of Nevada. In the first half of 2011, Company management decided to reorganize as a holding company to acquire and manage a number of companies in the medical services sector.

On June 22, 2011, the Company organized Medytox Medical Management Solutions Corp. ("MMMS"), a Florida corporation, as a wholly-owned subsidiary. On October 26, 2013, MMMS changed its name to Medytox Information Technology, Inc. ("MIT"). MIT provides information technology and management solutions to our subsidiaries and outside medical service providers. MIT operates from the corporate offices in West Palm Beach, Florida.

On July 26, 2011, the Company organized Medytox Institute of Laboratory Medicine, Inc. (“MILM”), a Florida corporation, as a wholly-owned subsidiary.  MILM was organized to acquire and manage medical testing laboratories. MILM operates from the corporate offices in West Palm Beach, Florida.

On August 22, 2011, the Company acquired 100% of Medical Billing Choices, Inc. ("MBC"), a privately-held North Carolina corporation. The company operates a medical billing service for a variety of medical providers throughout the southeastern United States from offices in Charlotte, North Carolina. MBC is also the main billing company for the Medytox-owned laboratories and allows Medytox to offer medical billing services to its customers.

On February 16, 2012, Medytox Diagnostics, Inc. (“MDI”), a wholly-owned subsidiary of the Company, entered into a Membership Interest Purchase Agreement for the purchase of 50.5% of the outstanding membership interests in Collectaway, LLC, a clinical laboratory located in Palm Beach County, Florida.  The name of Collectaway, LLC was changed to PB Laboratories, LLC. On October 12, 2012, MDI acquired the remaining 49.5% ownership in PB Laboratories, LLC that it did not already own. MDI now owns 100% of this laboratory.

On March 9, 2012, the Company formed Medytox Medical Marketing & Sales, Inc. ("MMM&S"), a Florida corporation, as a wholly-owned subsidiary that provides marketing for clinical laboratories that are owned by the Company. MMM&S operates from the corporate offices in West Palm Beach, Florida.

On September 10, 2012, the Company entered into an agreement to purchase all of the assets and intellectual property rights to the software known as "Medytox Advantage" that it did not already own from Dash Software, LLC for $150,000.

On December 7, 2012, MDI entered into an agreement to acquire 50.5% ownership in Biohealth Medical Laboratory, Inc., a Miami-based clinical laboratory. The Company immediately initiated an investment program to increase the clinical lab testing capacity of blood and urine specimens at Biohealth Medical Laboratory, Inc.

On January 1, 2013, MDI purchased 100% of the stock of Alethea Laboratories, Inc. ("Alethea").  Althea operates a licensed clinical lab in Las Cruces, New Mexico and is an enrolled Medicare provider.  

On January 29, 2013, the Company formed Advantage Reference Labs, Inc. ("Advantage"), a Florida corporation, as a wholly-owned subsidiary to provide reference, confirmation and clinical testing services. On October 14, 2013, Advantage changed its name to EPIC Reference Labs, Inc. ("EPIC").

On April 4, 2013, MDI purchased 100% of the membership interests of International Technologies, LLC ("International").  International operates a licensed clinical laboratory in Waldwick, New Jersey and is a licensed Medicare provider.

On July 2, 2013, a jury awarded MILM $2,906,844 on its breach of contract claim against Trident Laboratories, Inc. and its shareholders and awarded Seamus Lagan $750,000 individually against Christopher Hawley for defamatory postings on the internet. The jury rejected every claim made against the MILM parties.

On March 18, 2014, the Company’s wholly-owned subsidiary, MIT, purchased 100% of the stock of Clinlab, Inc. ("Clinlab"), a Florida corporation. Clinlab develops and markets laboratory information management systems.

27

On May 9, 2014, the Company formed Medical Mime, Inc. (“Mime”), a Florida corporation, as a wholly-owned subsidiary.

On May 23, 2014, Mime purchased certain net assets, primarily consisting of software, of GlobalOne Information Technologies, LLC (“GlobalOne”). GlobalOne developed software and provided services for the Electronic Records Management (“ERM”) segment of the medical industry.

Effective August 26, 2014 the Board of Directors elected to increase the size of the Board to five members.

On August 26, 2014, MDI purchased all of the outstanding stock of Epinex Diagnostics Laboratories, Inc. (“Epinex”), a California corporation. Epinex is a clinical laboratory in Tustin, California.

On September 11, 2014, William G. Forhan, Medytox Solutions Chief Executive Officer and Chairman of the Board of Directors, voluntarily resigned both positions. Mr. Forhan continues to serve as a member of the Board of Directors.

Mr. Forhan was employed as the Company’s Chief Executive Officer pursuant to the terms of an employment agreement dated October 1, 2012, as amended as of September 1, 2013. In connection with his voluntary resignation he entered into an agreement, to be effective as of the date of appointment of a new Chief Executive Officer of the Company, pursuant to which he will receive a severance of $500,000, payable in two installments, the first of $200,000 was paid prior to the effective date of resignation, and the balance to be paid no later than August 31, 2016. In addition, the Agreement provided that Mr. Forhan could participate in any executive bonus plan adopted for calendar year 2014. Mr. Forhan also agreed under the Agreement that any Company stock options previously issued to him, would remain outstanding, subject to their terms, for no longer than 24 months such that the options will expire no later than August 31, 2016. In addition, the Agreement provided, among other things, for the return and cancellation of 1,241,550 shares of Common Stock owned by Mr. Forhan; for the release by Mr. Forhan of any and all claims he may have had against the Company and/or its affiliates; and for Mr. Forhan to abide by certain restrictive covenants, including using his best efforts to protect and maintain the Company's confidential information.

On September 11, 2014, Seamus Lagan was unanimously appointed by the Board of Directors to succeed Mr. Forhan as the Chief Executive Officer. Mr. Lagan was also elected as a Director by the Board and Benjamin Frank was elected Chairman of the Board to succeed Mr. Forhan.

Plan of Operation

Medytox is a holding company that owns and operates businesses in the medical services sector. Medytox has invested in a strong sales team, a client services team and proprietary technologies to better serve the needs of a modern-day medical provider.

The Company seeks to become a leading provider of laboratory and related services and solutions to medical providers. To date, we have specialized in providing urine and blood drug toxicology and comprehensive pain medication monitoring programs to physicians, clinics and rehabilitation facilities in the United States. We intend to grow through the acquisition and/or formation of additional laboratory testing facilities and related businesses in the United States.

Results of Operations

For the three months ended September 30, 2014 compared to the three months ended September 30, 2013

Net Revenues

Net revenues were $18,215,967 for the three months ended September 30, 2014 compared to $13,012,150 for the three months ended September 30, 2013, an increase of $5,203,817, or 40%. The increase is primarily due to the Company’s subsidiaries Alethea and EPIC beginning operations in the first quarter of 2014. The increase was offset in part by the Company’s decision to increase our estimate of uncollectible amounts resulting in a reduction in gross revenues of $3,581,737. This adjustment was taken in order to more accurately reflect actual collections of amounts receivable in light of recent trends and was applied to all lab operations for the three months ended September 30, 2014, as reflected in the amounts noted below. Net revenues for the Company’s significant laboratory operations, by subsidiary, were: PB Labs $8,038,222 and $7,116,369 for the three months ended September 30, 2014 and 2013, respectively; Biohealth $6,760,960 and $5,858,503 for the three months ended September 30, 2014 and 2013, respectively; Alethea $2,559,788 and $-0- for the three months ended September 30, 2014 and 2013, respectively; EPIC $3,117,219 and $-0- for the three months ended September 30, 2014 and 2013, respectively and International $1,102,577 and $ -0- for the three months ended September 30, 2014 and 2013, respectively.

28

Results of Operations (Continued)

For the three months ended September 30, 2014 compared to the three months ended September 30, 2013

Operating Expenses and Other Income

For the three months ended September 30, 2014, our total operating expenses were $11,912,090 compared to $8,898,479 for the three months ended September 30, 2013 resulting in an increase of $3,013,611, or 34%. The increase is attributable to increases in direct costs of revenue of $844,990, general and administrative expenses of $1,369,209, sales and marketing expenses of $781,139, and depreciation and amortization of $285,559, offset by a decrease in legal fees related to the Trident lawsuit of $267,286. General and administrative expenses generally include corporate overhead, financial and administrative contracted services, legal fees, and consulting costs. The above increases are directly attributable to the increase in revenues of International, Alethea and EPIC.

Our income from operations for the three months ended September 30, 2014 was $6,303,877 as compared to $4,113,671 for the three months ended September 30, 2013.

Other expenses incurred during the three months ended September 30, 2014 included: (i) interest expense of $118,603 (2013: $68,785) and (ii) loss on legal settlement of $-0- (2013: $100,000); offset by (iii) gain on the settlement of assets of $-0- (2013: $400); and (v) other income of $152 (2013: $64).

Net income attributable to Medytox Solutions common shareholders for the three months ended September 30, 2014 was $2,339,607 compared to $1,891,218 for the three months ended September 30, 2013.

For the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013

Net Revenues

Net revenues were $49,045,205 for the nine months ended September 30, 2014 compared to $25,561,501 for the nine months ended September 30, 2013, an increase of $23,483,704, or 92%. The increase is primarily due to the Company’s subsidiaries 1) Biohealth being in operation for all of 2014 after starting operations in the second quarter of 2013 and 2) Alethea and EPIC beginning operations in the first quarter of 2014. The increase was offset in part by the Company’s decision to increase our estimate of uncollectible amounts resulting in a reduction in gross revenues of $3,581,737. This adjustment was taken in order to more accurately reflect actual collections of amounts receivable in light of recent trends and was applied to all lab operations as reflected in the amounts for the nine months ended September 30, 2014, noted below. Net revenues for the Company’s laboratory operations, by subsidiary, were: PB Labs $18,037,464 and $18,233,513 for the nine months ended September 30, 2014 and 2013, respectively; Biohealth $18,379,799 and $7,224,254 for the nine months ended September 30, 2014 and 2013, respectively; Alethea $6,212,945 and $-0- for the nine months ended September 30, 2014 and 2013, respectively; EPIC $8,328,831 and $-0- for the nine months ended September 30, 2014 and 2013, respectively; and International $1,139,048 and $-0- for the nine months ended September 30, 2014 and 2013, respectively.

Operating Expenses and Other Income

For the nine months ended September 30, 2014, our total operating expenses were $30,078,958 compared to $19,263,597 for the nine months ended September 30, 2013 resulting in an increase of $10,815,361, or 56%. The increase is attributable to increases in direct costs of revenue of $4,613,625, general and administrative expenses of $4,903,671, sales and marketing expenses of $1,583,739, and depreciation and amortization of $477,696, offset by a decrease in legal fees related to the Trident lawsuit of $763,370. General and administrative expenses generally include corporate overhead, financial and administrative contracted services, legal fees, and consulting costs. The above increases are directly attributable to the increase in revenues of Biohealth, Alethea and EPIC.

Our income from operations for the nine months ended September 30, 2014 was $18,966,247 as compared to $6,297,904 for the nine months ended September 30, 2013.

Other expenses incurred during the nine months ended September 30, 2014 included: (i) interest expense of $316,299 (2013: $332,387) and (ii) loss on legal settlement of $-0- (2013: $169,800); offset by (iii) gain on the disposition of subsidiary of $134,185 (2013: $-0-); (iv) gain on the settlement of assets of $-0- (2013: $750); and (v) other income (expense) of $405 (2013: $273).

Net income attributable to Medytox Solutions common shareholders for the nine months ended September 30, 2014 was $7,718,514 compared to $2,744,602 for the nine months ended September 30, 2013.

29

Disputed Segment

The dispute with Trident Laboratories, Inc. and its shareholders originated in 2012. The assets and liabilities of Trident were excluded from the individual consolidated balance sheet line items and presented separately as assets and liabilities from disputed activity and operating activity for 2013 was excluded from the consolidated statement of operations. In addition, the Company had reserved $397,918 of net income from the disputed activity for the period from August 22, 2011 (date of acquisition) through December 31, 2013. Effective March 31, 2014, the Company’s management believes that the net assets of Trident are not recoverable and as such, the Company has accounted for the disputed assets and liabilities as if they have been disposed, resulting in a gain on the disposition of $134,185. The net assets and liabilities attributable to the disputed activity are as follows at December 31, 2013:

Assets attributable to disputed activity	$	1,367,796
Liabilities attributable to disputed activity	$	1,104,063

Liquidity and Capital Resources

Overview

The Company historically has utilized cash from operations and various credit facilities to fund working capital needs, acquisitions and capital expenditures. Future cash needs for working capital, acquisitions and capital expenditures may require management to seek additional equity or obtain additional credit facilities. The sale of additional equity could result in additional dilution to the Company's shareholders. A portion of the Company's cash may be used to acquire or invest in complementary businesses or products or to obtain the right to use complementary technologies. From time to time, in the ordinary course of business, the Company evaluates potential acquisitions of such businesses, products or technologies.

For the nine months ended September 30, 2014, we funded our operations through cash provided by operations, while for the nine months ended September 30, 2013, we funded our operations through cash provided by operations, borrowings from third parties and sales of our common stock. Our principal use of funds during the nine months ended September 30, 2014 has been for payments on borrowings, acquisitions and general corporate expenses. Management believes that based on the current level of operations and cash flow from operations, the Company will have sufficient liquidity to fund anticipated expenses and other commitments for the next twelve months.

Liquidity and Capital Resources during the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013

As of September 30, 2014, we had cash of $1,763,728 and working capital of $7,407,669. The Company generated cash flow from operations of $7,940,427 for the nine months ended September 30, 2014 compared to cash provided by operations of $5,102,276 for the nine months ended September 30, 2013. The cash flow from operating activities for the nine months ended September 30, 2014 was primarily attributable to the Company's net income from operations of $11,534,233, increased by depreciation and amortization of $800,727, stock based compensation of $557,250, and bad debts of $15,630,857 offset by the gain on disposition of subsidiary of $134,185 and the net changes in operating assets and liabilities of $20,464,233. Cash provided by operations for the nine months ended September 30, 2013 was primarily attributable to the Company's net income from operations of $4,140,840, increased by depreciation and amortization of $323,031, stock issued for services of $147,500, stock-based compensation of $452,500, bad debt expense of $7,794,361, accretion of loan costs as interest of $155,342 and accretion of beneficial conversion feature as interest of $34,532, offset by net changes in operating assets and liabilities of $7,945080.

Cash used in investing activities was $2,986,308 and $1,593,212 for the nine months ended September 30, 2014 and 2013, respectively. Cash used in investing activities for the nine months ended September 30, 2014 included $1,417,979 for the purchase of property and equipment and cash paid for acquisitions of $1,600,000, offset by cash received in acquisitions of $31,671. Cash used in investing activities for the nine months ended September 30, 2013 was attributable to the purchase of property and equipment of $862,645 and cash paid for acquisitions of $735,052, offset by cash received for the sale of property and equipment of $750 and cash received in acquisitions of $3,735.

Cash used in financing activities was $7,331,807 and $2,744,802 for the nine months ended September 30, 2014 and 2013, respectively. Cash used in financing activities for the nine months ended September 30, 2014 included $3,815,719 of dividends on Series B Preferred Stock, payments on notes payable of $3,234,939, and payments on capital lease obligations of $281,149. Cash used in financing activities for the nine months ended September 30, 2013 included $103,949 for deferred loan costs, dividends on Series B Preferred Stock of $1,369,238, payments on notes payable of $2,278,910, payments on capital lease obligations of $86,705, payments on related party loans of $195,000 and common stock repurchased from lender of $100,000, offset by proceeds received from the issuance of notes payable of $1,300,000 and proceeds received from the sale of common stock of $116,000.

30

Liquidity and Capital Resources during the nine months ended September 30, 2014 compared to the nine months ended September 30, 2013 – (Continued)

Under terms of the Senior Secured Revolving Credit Facility agreement with TCA Global Credit Master Fund, LP, originally signed May 12, 2012 and as subsequently amended, the Company executed an Amended and Restated Revolving Promissory Note, due January 15, 2014, in the amount of $3,025,000. The note was extended by the lender from January 15, 2014 to September 15, 2014. The borrowings under this facility were repaid in full on September 8, 2014.

Off-Balance Sheet Arrangements

We currently have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experiences and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions and conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.

See Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and Note 2, “Summary of Significant Accounting Policies” in our audited consolidated financial statements as of and for the year ended December 31, 2013, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (“SEC”) on March 31, 2014.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

The disclosure required under this item is not required to be reported by smaller reporting companies.

Item 4. Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures

In connection with the preparation of this Quarterly Report on Form 10-Q, an evaluation was carried out by the Company's management, with the participation of the principal executive officer and the principal financial officer, of the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 ("Exchange Act")) as of September 30, 2014. Disclosure controls and procedures are designed to ensure that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to management, including the chief executive officer and the chief financial officer, to allow timely decisions regarding required disclosures.

Based on that evaluation, the Company's management concluded, as of the end of the period covered by this report, that the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective. In connection with such evaluation, management identified a material weakness in internal control over financial reporting. Insufficient staffing and accounting processes and procedures led to a lack of of contemporaneous documentation supporting the accounting for certain transactions. The Company is in the process of taking the following steps to remediate the material weakness: (i) increasing the staffing of its internal accounting department, including the addition of a new corporate controller, (ii) engaging outside independent consultants to assist in the analysis of complex accounting transactions, and (iii) implementing enhanced documentation procedures to be followed by the internal accounting department and outside independent consultants.

Notwithstanding such material weakness, management believes that the condensed consolidated financial statements included in this Form 10-Q fairly present in all material respects the Company's financial condition, results of operations and cash flows for the periods and dates presented.

(b) Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

31

PART II – OTHER INFORMATION

Item 1. Legal Proceedings.

During the course of business, litigation commonly occurs.  From time to time the Company may be a party to litigation matters involving claims against the Company. The Company operates in a highly regulated industry and employs personnel which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company's financial position or results of operations. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims below.

On July 2, 2013, a jury awarded Medytox Institute of Laboratory Medicine, Inc., its wholly-owned subsidiary ("MILM"), $2,906,844 on its breach of contract claim against Trident Laboratories, Inc. and its shareholders and awarded Seamus Lagan $750,000 individually against Christopher Hawley for defamatory postings on the internet. The jury rejected every claim made against the MILM parties. All appeals have been dismissed.

The Company filed an action on February 14, 2014 in the United States District Court for the Southern District of Florida against Reginald Samuels and Ralph Perricelli seeking, among other things, a declaration that the convertible debentures in the aggregate amount of $500,000 that the Company issued to Mr. Samuels and Mr. Perricelli as part of the consideration for the purchase of their interests in International Technologies, LLC are null and void. Mr. Samuels and Mr. Perricelli have been served and the litigation is ongoing.

On October 21, 2013, Mr. Samuels filed a complaint in the Superior Court of New Jersey (Bergen County) against the Company and Medytox Diagnostics, Inc. alleging breach of contract under his employment agreement and the agreement under which International Technologies, LLC was acquired; unjust enrichment; fraud; intentional and negligent misrepresentation; and breach of an implied duty of good faith and fair dealing and seeking an accounting. On December 20, 2013, Mr. Perricelli filed a similar action in the same court. The Company believes all these claims are without merit.

The action filed by Mr. Samuels has been removed to the federal court in the District of New Jersey. The action filed by Mr. Perricelli has been transferred to the Southern District of Florida.

Item 1A. Risk Factors.

The disclosure required under this item is not required to be reported by smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

On August 26, 2014, 100,000 shares of Series E Preferred Stock were issued to the seller in connection with the acquisition of Epinex Diagnostics Laboratories, Inc.

These securities were not registered under the Securities Act of 1933, as amended (the “Securities Act”), but were issued in reliance upon the exemption from registration provided by Section 4(2) of the Securities Act as a transaction by an issuer not involving a public offering.

Item 3. Defaults Upon Senior Securities.

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information.

None.

32

Item 6. Exhibits

Exhibit 3.1	Certificate of Designation for the Series E Convertible Preferred Stock, par value $.0001 per share, of Medytox Solutions, Inc. (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 28, 2014).
Exhibit 3.4	Amended and Restated Bylaws of Medytox Solutions, Inc. (1)
Exhibit 10.1	Stock Purchase Agreement, dated as of August 26, 2014, by and among Epinex Diagnostics Laboratories, Inc., Epinex Diagnostics, Inc., Medytox Diagnostics, Inc. and Medytox Solutions, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 28, 2014).
Exhibit 10.2	Agreement for the Retirement as CEO and Release of Any and All Claims  by and between Medytox Solutions, Inc. and William G. Forhan, dated August 26, 2014, effective as of September 11, 2014  (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 12, 2014).
Exhibit 10.3	Amendment to Consulting Agreement, by and between Medytox Solutions, Inc. and Alcimede LLC, dated as of September 11, 2014 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 12, 2014).
Exhibit 15	Acknowledgement Letter of Independent Registered Public Accounting Firm
Exhibit 31.1	Rule 13a-14(a) Certification by the Principal Executive Officer
Exhibit 31.2	Rule 13a-14(a) Certification by the Principal Financial Officer
Exhibit 32.1	Certification by the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 32.2	Certification by the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 101.INS	XBRL Instance Document
Exhibit 101.SCH	XBRL Schema Document
Exhibit 101.CAL	XBRL Calculation Link base Document
Exhibit 101.DEF	XBRL Definition Link base Document
Exhibit 101.LAB	XBRL Label Link base Document
Exhibit 101.PRE	XBRL Presentation Link base Document

(1) Previously filed with the original Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 19, 2014 and incorporated by reference herein.  

33

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	MEDYTOX SOLUTIONS, INC.
Date: March 6, 2015	By: /s/ Seamus Lagan
	Seamus Lagan
	Chief Executive Officer (Principal Executive Officer)

Date: March 6, 2015	By: /s/ Jace Simmons
	Jace Simmons
	Chief Financial Officer (Principal Financial Officer)

34